| Drug Name | ***0163 |
| Description |
A novel immunotherapy is human natural killer cells engineered to express a bivalent third generation chimeric antigen receptor (CAR) comprising two anti-CD7 nanobodies. The product is in preclinical development for the treatment of T cell malignancies. |
| Target | CD7 |
| Drug Modality | CAR-NK Cells |
| Indication | Cancer |
| Product Category | Cancer Immunotherapy |
| Mechanism of Action | Targeting T-Cell Antigen CD7 |
| Status | Preclinical |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |